Abe Ikubo & Katayama is a market-leading intellectual property practice with a proven track record across the full range of IP, especially in IP infringement litigation. The firm offers strong technical knowledge in the fields of pharmaceuticals, chemicals, biotechnology, electronics and telecommunications. Eiji Katayama and Hiroshi Kobayashi are key contacts.
Client feedback
“Great work for litigations and invalidation trials with their excellent knowledge and experience as well as their flexible thinking.” – Intellectual property
Mami Hino
“She is willing to meet clients' needs with her flexible thinking and excellent knowledge and experience. Her communication skills, including internal and external networking, are also great. She manages risks appropriately. She is a trusted lawyer.”
Work highlights
Represented Eisai in a declaratory judgment case where Nipro sought confirmation of non-infringement and invalidity of Eisai's patents related to the cancer drug Halaven. The Tokyo District Court and subsequently the IP High Court dismissed Nipro's claims for lack of justiciable interest, upholding Eisai's position. This case has significant implications for patent linkage practices in Japanese pharmaceutical approvals.
Key clients
Bristol Myers Squibb, SoftBank
